Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Age-Related Changes in the Interaction of Acute Myeloid Leukemia with the Bone Marrow Microenvironment Correlate with Response to Treatment and Survival: A Role for L-Selectin

Joe C Huang, MD, Yifan Lu, B.S., Julia Sidorova, PhD, Sylvia Chien, Vivian Oehler, MD, Kenneth J Kopecky, PhD, Pamela S. Becker, MD PhD

Blood (2016) 128 (22): 5063.

https://doi.org/10.1182/blood.V128.22.5063.5063

Published: 2016

Journal Articles

Prognostic Significance Of NPM1 mutations In The Absence Of FLT3 -ITD in Older Patients With AML: A SWOG Report

Fabiana Ostronoff, MD, Megan Othus, PhD, Soheil Meshinchi, MD, PhD, John E. Godwin, MD, MS, Kenneth J. Kopecky, PhD, Alan List, MD, Vivian G. Oehler, MD, Stephen Petersdorf, MD, Era L. Pogosova-Agadjanyan, Jerald Radich, MD, Cheryl L. Willman, MD, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD

Blood (2013) 122 (21): 1315.

https://doi.org/10.1182/blood.V122.21.1315.1315

Published: 2013

Journal Articles

Single-Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (AML): Validation in Two Independent Sample Sets From ECOG and SWOG Trials.

Alessandra Cesano, M.D., Ph.D., Cheryl L Willman, MD, Kenneth J. Kopecky, PhD, Urte Gayko, Ph.D., Santosh Putta, Ph.D., Brent Louie, Ph.D., Matt Westfall, Ph.D., Norman Purvis, Ph.D., David Spellmeyer, PhD, Carol Marimpietri, James Hackett, Ph.D., Jing Shi, Elisabeth Paietta, PhD, Martin S. Tallman, MD, Larry D Cripe, MD, Susan K. Atwater, MD, Frederick R. Appelbaum, MD, Jerald P. Radich, MD

Blood (2012) 120 (21): 2489.

https://doi.org/10.1182/blood.V120.21.2489.2489

Published: 2012

Journal Articles

Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18–60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG

Era L. Pogosova-Agadjanyan, Kenneth J. Kopecky, PhD, Stephen Petersdorf, MD, Harry Paul Erba, MD, PhD, Richard M. Stone, MD, Soheil Meshinchi, MD, PhD, Thomas J. Nevill, MD, FRCPC, Jerald P. Radich, MD, Leif Stenke, MD, PhD, Marilyn L Slovak, PhD, Robert K Stuart, MD, Martin S. Tallman, MD, Cheryl L Willman, MD, Rebecca M. Mortensen, Breanna L. Wentz, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD

Blood (2011) 118 (21): 2520.

https://doi.org/10.1182/blood.V118.21.2520.2520

Published: 2011

Journal Articles

Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data

Laura F Newell, MD, Megan Othus, PhD, Roland B. Walter, MD, PhD, Stephen H. Petersdorf, MD, Thomas Chauncey, MD, PhD, Jeanne E. Anderson, MD, John E. Godwin, MD, MS, Kenneth J. Kopecky, PhD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2011) 118 (21): 1446.

https://doi.org/10.1182/blood.V118.21.1446.1446

Published: 2011

Journal Articles

Prognostic Implications of the IDH1 synonymous SNP rs11554137 In Pediatric and Adult AML: a Children's Oncology Group and Southwest Oncology Group Study

Blood (2010) 116 (21): 2737.

https://doi.org/10.1182/blood.V116.21.2737.2737

Published: 2010

Journal Articles

Clinical and Functional Relevance of Interactions Between the Bone Marrow Stormal Microenvironment and Primary Human Acute Myeloid Leukemia (AML) Cells

Soumit K. Basu, MD, PhD, Sylvia Chien, Xin Zhao, MD, Kenneth J. Kopecky, PhD, Frederick R. Appelbaum, MD, Thalia Papayannopoulou, MD, DSci, Elihu H. Estey, MD, Pamela S. Becker, MD, PhD

Blood (2010) 116 (21): 2756.

https://doi.org/10.1182/blood.V116.21.2756.2756

Published: 2010

Journal Articles

A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial

Jerald P. Radich, MD, Kenneth J. Kopecky, PhD, Suzanne Kamel-Reid, PhD, Wendy Stock, MD, Elisabeth Paietta, PhD, Martha Wadleigh, MD, Richard A. Larson, MD, Peter D. Emanuel, MD, Martin S. Tallman, MD, Jeffrey Lipton, MD, FRCPC, Stephen Couban, BSc, MD, Michael W. Deininger, MD, PhD, Frederick R. Appelbaum, MD, Brian J. Druker, MD

Blood (2010) 116 (21): LBA-6.

https://doi.org/10.1182/blood.V116.21.LBA-6.LBA-6

Published: 2010

Journal Articles

Over-Expression of Novel IRF8 Splice Variants Is Associated with a Significant Decrease In Relapse-Free Survival In Adult AML Patients.

Era L. Pogosova-Agadjanyan, Kenneth J. Kopecky, PhD, Hana Lee, Jeanne E. Anderson, MD, John E. Godwin, MD, MS, Alan F. List, Soheil Meshinchi, MD, PhD, Vivian Oehler, MD, Stephen H. Petersdorf, MD, Cheryl L. Willman, MD, Frederick R. Appelbaum, MD, Jerald P. Radich, MD, Derek L. Stirewalt, MD

Blood (2010) 116 (21): 1679.

https://doi.org/10.1182/blood.V116.21.1679.1679

Published: 2010

Journal Articles

Phase II Studies of Different Schedules and Doses of the Farnesyl Transferase Inhibitor Tipifarnib (R115777, Zarnestra, NSC-702818) for Patients of Age 70 or Older with Previously Untreated Acute Myeloid Leukemia (AML): A North American Intergroup Study (S0432).

Harry P. Erba, MD, PhD, Kenneth J. Kopecky, PhD, Mark H. Kirschbaum, MD, Martin S. Tallman, MD, Richard A. Larson, MD, Cheryl L. Willman, MD, Marilyn L. Slovak, PhD, Holly M. Gundacker, MA, Frederick R. Appelbaum, MD

Blood (2007) 110 (11): 440.

https://doi.org/10.1182/blood.V110.11.440.440

Published: 2007

Journal Articles

Very Late Antigen-4 (VLA-4) Expression by AML Blasts: Correlation of VCAM-1 Binding to Overall Survival.

Pamela S. Becker, MD, PhD, Thalia Papayannopoulou, MD, DSci, Kenneth J. Kopecky, PhD, Adrianne N. Hanks, BA, John M. Harlan, MD, Cheryl L. Willman, MD, Frederick R. Appelbaum, MD

Blood (2005) 106 (11): 2365.

https://doi.org/10.1182/blood.V106.11.2365.2365

Published: 2005

NARROW

Age-Related Changes in the Interaction of Acute Myeloid Leukemia with the Bone Marrow Microenvironment Correlate with Response to Treatment and Survival: A Role for L-Selectin

Prognostic Significance Of NPM1 mutations In The Absence Of FLT3 -ITD in Older Patients With AML: A SWOG Report

Single-Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (AML): Validation in Two Independent Sample Sets From ECOG and SWOG Trials.

Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18–60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG

Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data

Prognostic Implications of the IDH1 synonymous SNP rs11554137 In Pediatric and Adult AML: a Children's Oncology Group and Southwest Oncology Group Study

Clinical and Functional Relevance of Interactions Between the Bone Marrow Stormal Microenvironment and Primary Human Acute Myeloid Leukemia (AML) Cells

A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial

Over-Expression of Novel IRF8 Splice Variants Is Associated with a Significant Decrease In Relapse-Free Survival In Adult AML Patients.

Phase II Studies of Different Schedules and Doses of the Farnesyl Transferase Inhibitor Tipifarnib (R115777, Zarnestra, NSC-702818) for Patients of Age 70 or Older with Previously Untreated Acute Myeloid Leukemia (AML): A North American Intergroup Study (S0432).

Very Late Antigen-4 (VLA-4) Expression by AML Blasts: Correlation of VCAM-1 Binding to Overall Survival.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only